FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2294858745> ?p ?o ?g. }

• W2294858745 endingPage "1228" @default.
• W2294858745 startingPage "1217" @default.
• W2294858745 abstract "Bisphosphonates (BPs) are a class of bone resorptive drug with a high affinity for the hydroxyapatite structure of bone matrices that are used for the treatment of osteoporosis. However, clinical application is limited by a common toxicity, BP-related osteonecrosis of the jaw. There is emerging evidence that BPs possess anticancer potential, but exploitation of these antiproliferative properties is limited by their toxicities. We previously reported the utility of a cationic amphipathic fusogenic peptide, RALA, to traffic anionic nucleic acids into various cell types in the form of cationic nanoparticles. We hypothesized that complexation with RALA could similarly be used to conceal a BP’s hydroxyapatite affinity, and to enhance bioavailability, thereby improving anticancer efficacy. Incubation of RALA with alendronate, etidronate, risedronate, or zoledronate provoked spontaneous electrostatic formation of cationic nanoparticles that did not exceed 100 nm in diameter and that were stable over a range of temperatures and for up to 6 h. The nanoparticles demonstrated a pH responsiveness, possibly indicative of a conformational change, that could facilitate release of the BP cargo in the endosomal environment. RALA/BP nanoparticles were more potent anticancer agents than their free BP counterparts in assays investigating the viability of PC3 prostate cancer and MDA-MB-231 breast cancer cells. Moreover, RALA complexation potentiated the tumor growth delay activity of alendronate in a PC3 xenograft model of prostate cancer. Taken together, these findings further validate the use of BPs as repurposed anticancer agents." @default.
• W2294858745 created "2016-06-24" @default.
• W2294858745 creator A5001973427 @default.
• W2294858745 creator A5027622358 @default.
• W2294858745 creator A5027801789 @default.
• W2294858745 creator A5041832272 @default.
• W2294858745 creator A5056196865 @default.
• W2294858745 creator A5057590715 @default.
• W2294858745 creator A5069406381 @default.
• W2294858745 creator A5071021600 @default.
• W2294858745 creator A5080850326 @default.
• W2294858745 creator A5081151755 @default.
• W2294858745 creator A5087663313 @default.
• W2294858745 creator A5088904574 @default.
• W2294858745 creator A5089145091 @default.
• W2294858745 date "2016-03-22" @default.
• W2294858745 modified "2023-09-30" @default.
• W2294858745 title "Potentiating the Anticancer Properties of Bisphosphonates by Nanocomplexation with the Cationic Amphipathic Peptide, RALA" @default.
• W2294858745 cites W1906721103 @default.
• W2294858745 cites W1967657530 @default.
• W2294858745 cites W1982855449 @default.
• W2294858745 cites W1993890329 @default.
• W2294858745 cites W1995737576 @default.
• W2294858745 cites W1996523699 @default.
• W2294858745 cites W2012426941 @default.
• W2294858745 cites W2017267215 @default.
• W2294858745 cites W2023212573 @default.
• W2294858745 cites W2025204533 @default.
• W2294858745 cites W2040170408 @default.
• W2294858745 cites W2047672333 @default.
• W2294858745 cites W2053115200 @default.
• W2294858745 cites W2078057254 @default.
• W2294858745 cites W2078413016 @default.
• W2294858745 cites W2084503634 @default.
• W2294858745 cites W2098528749 @default.
• W2294858745 cites W2106008904 @default.
• W2294858745 cites W2106474221 @default.
• W2294858745 cites W2113294064 @default.
• W2294858745 cites W2124166505 @default.
• W2294858745 cites W2159436449 @default.
• W2294858745 cites W2164308010 @default.
• W2294858745 cites W2171745736 @default.
• W2294858745 cites W2323005812 @default.
• W2294858745 doi "https://doi.org/10.1021/acs.molpharmaceut.5b00670" @default.
• W2294858745 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26954700" @default.
• W2294858745 hasPublicationYear "2016" @default.
• W2294858745 type Work @default.
• W2294858745 sameAs 2294858745 @default.
• W2294858745 citedByCount "30" @default.
• W2294858745 countsByYear W22948587452016 @default.
• W2294858745 countsByYear W22948587452017 @default.
• W2294858745 countsByYear W22948587452018 @default.
• W2294858745 countsByYear W22948587452019 @default.
• W2294858745 countsByYear W22948587452020 @default.
• W2294858745 countsByYear W22948587452021 @default.
• W2294858745 countsByYear W22948587452022 @default.
• W2294858745 countsByYear W22948587452023 @default.
• W2294858745 crossrefType "journal-article" @default.
• W2294858745 hasAuthorship W2294858745A5001973427 @default.
• W2294858745 hasAuthorship W2294858745A5027622358 @default.
• W2294858745 hasAuthorship W2294858745A5027801789 @default.
• W2294858745 hasAuthorship W2294858745A5041832272 @default.
• W2294858745 hasAuthorship W2294858745A5056196865 @default.
• W2294858745 hasAuthorship W2294858745A5057590715 @default.
• W2294858745 hasAuthorship W2294858745A5069406381 @default.
• W2294858745 hasAuthorship W2294858745A5071021600 @default.
• W2294858745 hasAuthorship W2294858745A5080850326 @default.
• W2294858745 hasAuthorship W2294858745A5081151755 @default.
• W2294858745 hasAuthorship W2294858745A5087663313 @default.
• W2294858745 hasAuthorship W2294858745A5088904574 @default.
• W2294858745 hasAuthorship W2294858745A5089145091 @default.
• W2294858745 hasConcept C102747710 @default.
• W2294858745 hasConcept C121608353 @default.
• W2294858745 hasConcept C12554922 @default.
• W2294858745 hasConcept C126322002 @default.
• W2294858745 hasConcept C1491633281 @default.
• W2294858745 hasConcept C15083742 @default.
• W2294858745 hasConcept C155672457 @default.
• W2294858745 hasConcept C171250308 @default.
• W2294858745 hasConcept C178790620 @default.
• W2294858745 hasConcept C181389837 @default.
• W2294858745 hasConcept C183882617 @default.
• W2294858745 hasConcept C185592680 @default.
• W2294858745 hasConcept C192562407 @default.
• W2294858745 hasConcept C2776541429 @default.
• W2294858745 hasConcept C2777251235 @default.
• W2294858745 hasConcept C2780192828 @default.
• W2294858745 hasConcept C502942594 @default.
• W2294858745 hasConcept C53227056 @default.
• W2294858745 hasConcept C55493867 @default.
• W2294858745 hasConcept C71924100 @default.
• W2294858745 hasConcept C86803240 @default.
• W2294858745 hasConcept C96232424 @default.
• W2294858745 hasConcept C98274493 @default.
• W2294858745 hasConceptScore W2294858745C102747710 @default.
• W2294858745 hasConceptScore W2294858745C121608353 @default.
• W2294858745 hasConceptScore W2294858745C12554922 @default.
• W2294858745 hasConceptScore W2294858745C126322002 @default.

• next